Siemens Healthcare has announced its first molecular imaging biomarker production facility in Chennai, India. The facility enable the healthcare providers in and around Chennai to access the positron emission tomography-computed tomography (PET-CT) technology to diagnose patients with life-threatening diseases, such as cancer and cardiac and neurological ailments. With this facility, Siemens makes another investment in strengthening critical healthcare infrastructure in the country to elevate the level of available healthcare services.

 The facility will feature a Siemens Eclipse(TM) HP cyclotron and will be Siemens' first molecular imaging biomarker production facility in India. The Eclipse cyclotron will be deployed to manufacture fluorodeoxyglucose (FDG), the imaging biomarker used in PET-CT facilities to assist with diagnosis and staging of disease processes and to monitor cellular response to treatments, such as chemotherapy and radiotherapy.

 Speaking on this initiative ,Michael Reitermann, chief executive officer, Molecular Imaging, Siemens Healthcare said "As advancements in molecular imaging move forward, it is imperative that this technology is made available to everyone in order to better diagnose and treat life-threatening diseases".